Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - betaxolol hydrochloride, quantity: 5.6 mg/ml (equivalent: betaxolol, qty 5 mg/ml) - eye drops, solution - excipient ingredients: purified water; disodium edetate; sodium chloride; hydrochloric acid; benzalkonium chloride; sodium hydroxide - indications as at 23 march 1999: betoquin eye drops 0.5% have been shown to be effective in lowering intraocular pressure and are indicated in the treatment of ocular hypertension or chronic open angular glaucoma. betoquin eye drops 0.5% may be used alone or in combination with other iop-lowering medication.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - betaxolol hydrochloride, quantity: 5.6 mg/ml - eye drops, solution - excipient ingredients: benzalkonium chloride; sodium hydroxide; sodium chloride; hydrochloric acid; disodium edetate; purified water - indications as at 23 march 1999: betoptic 0.5% have been shown to be effective in lowering intraocular pressure and are indicated in the treatment of ocular hypertension or chronic open angular glaucoma. betoptic eye drops 0.5% may be used alone or in combination with other iop-lowering medication.

Kenya - English - Pharmacy and Poisons Board

novartis pharma ag litchtstrasse 35, 4056 basel, switzerland - betaxolol hydrochloride - eye drops, solution - betaxolol hydrochloride 5mg/ml - betaxolol

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

sawai pharmaceutical co.,ltd. - betaxolol hydrochloride - colorless to faint yellow limpid ophthalmic solution, (cap) white, (bottle) colorless

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

nitto medic co., ltd. - betaxolol hydrochloride - colorless to slightly yellow limpid ophthalmic solution, 5 ml, (cap) white, (label) white label with pale purple band, (bottle) clear

Philippines - English - FDA (Food And Drug Administration)

alcon laboratories (phils.), inc. - betaxolol (as hydrochloride) - sterile ophthalmic solution - 5.6mg/ ml (equivalent to betaxolol base 5mg/ ml)

United States - English - NLM (National Library of Medicine)

alcon - betaxolol hydrochloride (unii: 6x97d2xt0o) (betaxolol - unii:o0zr1r6rz2) - solution/ drops - 5.6 mg in 1 ml - betoptic ophthalmic solution has been shown to be effective in lowering intraocular pressure and is indicated in the treatment of ocular hypertension and chronic open-angle glaucoma. it may be used alone or in combination with other anti-glaucoma drugs. in clinical studies betoptic was safely used to lower intraocular pressure in 47 patients with both glaucoma and reactive airway disease who were followed for a mean period of 15 months. however, caution should be used in treating patients with severe reactive airway disease or a history of asthma. hypersensitivity to any component of this product. betoptic ophthalmic solution is contraindicated in patients with sinus bradycardia, greater than a first degree atrioventricular block, cardiogenic shock, or patients with overt cardiac failure.

United States - English - NLM (National Library of Medicine)

alcon laboratories, inc. - betaxolol hydrochloride (unii: 6x97d2xt0o) (betaxolol - unii:o0zr1r6rz2) - kit - betoptic® pilo ophthalmic suspension is indicated for the reduction of elevated intraocular pressure in patients with primary open-angle glaucoma and ocular hypertension who are insufficiently responsive to betoptic® -s (failed to achieve target iop determined after multiple measurements over time). it is not known whether betoptic® pilo is equivalent in iop lowering efficacy to the administration of betoptic® -s 0.25% and pilocarpine 1.75% dosed separately. it is not known whether betoptic® pilo is equivalent to other beta-blockers given in combination with pilocarpine. betoptic® pilo ophthalmic suspension is contraindicated in patients with sinus bradycardia, greater than a first degree atrioventricular heart block, cardiogenic shock or patients with overt cardiac failure. betoptic® pilo ophthalmic suspension is also contraindicated in conditions where miosis is undesirable (e.g., peripheral anterior synechia, trauma, acute inflammatory disease of the anterior chamber, glaucoma occurring or persisting

United States - English - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - betaxolol hydrochloride (unii: 6x97d2xt0o) (betaxolol - unii:o0zr1r6rz2) - betoptic s® (betaxolol hydrochloride ophthalmic suspension) 0.25% is indicated for the treatment of elevated intraocular pressure (iop) in patients with chronic open-angle glaucoma or ocular hypertension. betoptic s is contraindicated in patients with: - sinus bradycardia - greater than a first degree atrioventricular (av) block - cardiogenic shock - patients with overt cardiac failure - hypersensitivity to any component of this product risk summary there are no adequate and well-controlled studies of betoptic s administration in pregnant women to inform a drug-associated risk. there are limited data with the use of betaxolol eye drops in pregnant women. epidemiological studies have not revealed malformative effects but show a risk for intrauterine growth retardation when beta-blockers are administered by the oral route. in animal reproductive studies, no drug-induced maternal toxicity or teratogenicity was observed at clinically relevant doses (see data) . because animal reproductive studies are not always

Malta - English - Malta Medicines Authority

novartis ireland limited vista building, elm park, merrion road, ballsbridge, dublin 4,, ireland - betaxolol hydrochloride - eye drops, suspension - betaxolol hydrochloride 2.5 mg/ml - ophthalmologicals